White Papers
Sponsored
Transformational value - preparing for a decade of radical change
The pharmaceutical industry is at an inflection point, where …
21481 items found
Views & Analysis
How companies can encourage more diversity and inclusion in pharma
September is Global Diversity and Inclusion month – David Peacock, …
News
Switzerland's ender to provide rapid COVID-19 diagnostics tests for cabin crew
ender diagnostics, a Swiss firm specialising in rapid molecular …
Views & Analysis
Unpleasant truth: the pandemic, record debt and our opportunity for sustainability
Sandoz’s Pierre Bourdage looks at the unexpected secondary impacts of …
News
UK government invests £32m in health tech projects
The UK government is to invest £32 million ($41.5 million) in six …
News
After a nay from NICE, Scotland says aye to J&J’s Spravato
NHS patients with treatment-resistant depression in Scotland will be …
News
Verona to test COPD hopeful ensifentrine in COVID-19 patients
Verona Pharma is starting a pilot study of its inhaled respiratory …
News
Pharma ‘must not dodge liability for harm in COVID-19 vaccine trials’
An EU consumer body has urged the European Commission to keep …
News
Trump will not interfere with vaccine approval process, FDA chief reassures staff
As readouts for crucial late-stage coronavirus vaccine trials …
Events
Partner Content
2nd Inflammasome Therapeutics Summit
Built with Inflammasome Therapeutics, GSK, and Novartis , the 2nd …
News
BioXcel's phase 3 schizophrenia film has blockbuster potential, say analysts
A sublingual film for acute agitation in schizophrenia and bipolar …
Views & Analysis
Digital success for pharma services in a uncertain world
Laura Morrill from ECI Partners looks at why data and technology are …
News
ESC: MSD/Bayer's Verquvo disappoints in heart failure trial
Bayer and MSD's hopes of expanding the use of Verquvo in heart failure have been dashed by a failed phase 3 trial.
Market Access
Sponsored
Bridging research and clinical guidelines – interactive stra...
Medical affairs is evolving. Understanding how to harness real-world data and digital insights is essential.
Market Access
12 questions with: Daniel Kohlstaedt
Daniel Kohlstaedt, managing director of PurpleLeaf Strategy, with more than 18 years of experience in pharma, talks about his journey through the industry.
R&D
Life Sciences Industry Report - Biologics and Generics
The importance of biosimilars only continues to grow, driven by the potential savings they are able to deliver to healthcare systems.
R&D
Increasing trial efficiency: Adityo Prakash talks small data...
Adityo Prakash, founder and CEO of Verseon, discusses small datasets, real-world scenarios, and organoids.
Oncology
Life Sciences Industry Report - Oncology
Developments in the oncology space in 2024 brought hope to both industry and patients.
Partner Content
Partner Content
The Antifibrotic Drug Development Summit returns this Novemb...
Harness cross-fibrotic insights and make new connections this November in Boston
R&D
Partner Content
Revolutionising Clinical Trials: Evolution Summit 2025 Retur...
Marcus Evans is proud to announce the Evolution Summit September 2025, an exclusive, invitation-only event bringing together leading clinical trial executives, innovative suppliers
